Off-label pasireotide treatment in one insulinoma patient with an atypical presentation and intolerant to diazoxide

Endocrine. 2020 Nov;70(2):435-438. doi: 10.1007/s12020-020-02406-1. Epub 2020 Jul 3.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diazoxide / therapeutic use
  • Humans
  • Insulinoma*
  • Off-Label Use
  • Pancreatic Neoplasms* / drug therapy
  • Somatostatin / analogs & derivatives

Substances

  • Somatostatin
  • pasireotide
  • Diazoxide